RCT | Insulin degludec is noninferior to insulin detemir for the treatment of pregnant women with type 1 diabetes
16 Mar, 2023 | 12:59h | UTCInsulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)